Spark Therapeutics Prices $350M Offering

8/4/17

PHILADELPHIA, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (NASDAQ:ONCE) announced today the pricing of an underwritten public offering of 4,605,264 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a public offering price of $76.00 per share, before offering discounts. The offering will result in aggregate net proceeds of approximately $330.8 million to Spark, after deducting underwriting discounts and before offering expenses. In addition, Spark has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 690,789 shares at the public offering price, less the underwriting discount. The offering is expected to close on or about August 9, 2017, subject to customary closing conditions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Spark Therapeutics

Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, such as hemophilia. Spark has ongoing clinical trials investigating gene therapies in hemophilia A and B. SPK-8011 is in an ongoing, dose-escalation Phase 1/2 clinical trial as a potential one-time therapy for hemophilia A. Spark retains full global commercialization rights to the SPK-FVIII program. SPK-9001, which has received both breakthrough therapy and orphan product designations by the U.S. Food and Drug Administration (FDA), and access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency (EMA), is in a Phase 1/2 clinical trial for hemophilia B and is being developed in collaboration with Pfizer, Inc. Our most advanced investigational candidate, with proposed trade name LUXTURNA™ (voretigene neparvovec), is currently under Priority Review with FDA for the treatment of biallelic RPE65-mediated IRD and has been designated as a drug for a rare pediatric disease. The marketing authorization application for LUXTURNA has been submitted to EMA for the treatment of vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations. LUXTURNA has received breakthrough therapy and orphan product designations from FDA and orphan product designations from EMA. The pipeline also includes SPK-7001 in an ongoing Phase 1/2 clinical trial for choroideremia.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.